INITIALL, SJALL23H, SJALL23T for first-line treatment of acute lymphoblastic leukemia (Originally presented on 6/25/24)

Wednesday, July 17, 2024, 2:00 PM - 3:00 PM

This program will introduce pharmacy staff members to the new ALL protocol due to open this year.

During the July 17th ENCORE presentation, any new information/updates available will also be discussed.

1. Outline differences between B- and T-cell ALL.
2. Discuss changes in ALL risk stratification terminology at St. Jude.
3. Review new front-line protocols for the management of ALL at St. Jude.

Attend Live - Marlo Thomas GEC - Meeting Room 3
CLICK HERE FOR WEBEX

REMINDERS FOR CLAIMING CE:

**CE Credit for this presentation is only available once (either on 6/25 or 7/17)**
(1) Your CloudCME profile must contain your NABP# and month/day of your date of birth or CE will not be awarded.
(2) Log your attendance during the event (within 2 hours after): Attendance Code for this event= 6295
-See the help section for instructions on how to log attendance: Click here for HELP.   
(3) Complete the test and evaluation (under ‘My CME’)

Confirm CE appears on your NABP profile within 4 weeks of the event and contact [email protected] if any questions or concerns.

St. Jude Children's Research Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

St. Jude Children’s Research Hospital designates this Live Activity for a maximum of 1.00 ACPE Credits^TM. Participants should only claim credit commensurate with the extent of their participation in the activity.

ACPE - Accreditation Council for Pharmacy Education (1.00 hours)

Mitigation of Relevant Financial Relationships

St Jude Children's Research Hospital adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (ie, companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.